In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology

Annals of Neurology

Volumn 79, Issue 5, 2016, Pages 794-805

  Herwerth, Marina ^a,b,c   Kalluri, Sudhakar Reddy ^a   Srivastava, Rajneesh ^a   Kleele, Tatjana ^b   Kenet, Selin ^b   Illes, Zsolt ^d,e   Merkler, Doron ^f,g,h   Bennett, Jeffrey L ⁱ   Misgeld, Thomas ^b,c,j,k   Hemmer, Bernhard ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Technische Universität München Munich Cluster for Systems Neurology   (Germany)

^d UNIVERSITY OF PÉCS   (Hungary)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF GENEVA   (Switzerland)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^k Munich Center for Integrated Protein Science   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; COMPLEMENT COMPONENT C1Q;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTE DEPLETION; AXONAL INJURY; CELL SURVIVAL; COMPLEMENT INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; IN VIVO STUDY; MALE; MOUSE; MYELOOPTIC NEUROPATHY; NERVE FIBER DEGENERATION; NEUROIMAGING; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; SWELLING; WHITE MATTER;

EID: 84963876992     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24630     Document Type: Article

References (63)

1. Coleman MP, Perry VH,. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 2002; 25: 532-537.
2. Trapp BD, Peterson J, Ransohoff RM, et al., Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285.
3. Schirmer L, Antel JP, Brück W, Stadelmann C,. Axonal loss and neurofilament phosphorylation changes accompany lesion development and clinical progression in multiple sclerosis. Brain Pathol 2011; 21: 428-440.
4. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al., The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
5. Lennon VA, Wingerchuk DM, Kryzer TJ, et al., A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
6. Lennon VA, Kryzer TJ, Pittock SJ, et al., IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
7. Paul F, Jarius S, Aktas O, et al., Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007; 4: e133.
8. Kalluri SR, Illes Z, Srivastava R, et al., Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol 2010; 67: 1201-1208.
9. Bennett JL, Lam C, Kalluri SR, et al., Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009; 66: 617-629.
10. Jarius S, Wildemann B,. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 6: 383-392.
11. Misu T, Fujihara K, Kakita A, et al., Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007; 130 (pt 5): 1224-1234.
12. Roemer SF, Parisi JE, Lennon VA, et al., Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130: 1194-1205.
13. Wrzos C, Winkler A, Metz I, et al., Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions. Acta Neuropathol 2014; 127: 523-538.
14. Bradl M, Misu T, Takahashi T, et al., Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66: 630-643.
15. Asavapanumas N, Verkman AS,. Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury. Acta Neuropathol Commun 2014; 2: 48.
16. Saadoun S, Waters P, Bell BA, et al., Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010; 133 (pt 2): 349-361.
17. Keegan M, Pineda AA, McClelland RL, et al., Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002; 58: 143-146.
18. Lucchinetti CF, Mandler RN, McGavern D, et al., A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125 (pt 7): 1450-1461.
19. Misu T, Höftberger R, Fujihara K, et al., Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 2013; 125: 815-827.
20. Kerschensteiner M, Schwab ME, Lichtman JW, Misgeld T,. In vivo imaging of axonal degeneration and regeneration in the injured spinal cord. Nat Med 2005; 11: 572-577.
21. Nikic I, Merkler D, Sorbara C, et al., A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2011; 17: 495-499.
22. Williams PR, Marincu BN, Sorbara CD, et al., A recoverable state of axon injury persists for hours after spinal cord contusion in vivo. Nat Commun 2014; 5: 5683.
23. Jarius S, Paul F, Franciotta D, et al., Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011; 306: 82-90.
24. Yang Y, Vidensky S, Jin L, et al., Molecular comparison of GLT1 + and ALDH1L1 + astrocytes in vivo in astroglial reporter mice. Glia 2010; 59: 200-207.
25. Brill MS, Lichtman JW, Thompson W, et al., Spatial constraints dictate glial territories at murine neuromuscular junctions. J Cell Biol 2011; 195: 293-305.
26. Doerflinger NH, Macklin WB, Popko B,. Inducible site-specific recombination in myelinating cells. Genesis 2003; 35: 63-72.
27. Madisen L, Zwingman TA, Sunkin SM, et al., A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci 2010; 13: 133-140.
28. Ma T, Yang B, Gillespie A, et al., Generation and phenotype of a transgenic knockout mouse lacking the mercurial-insensitive water channel aquaporin-4. J Clin Invest 1997; 100: 957-962.
29. Herwerth M, Jensen V, Novak M, et al., D4 dopamine receptors modulate NR2B NMDA receptors and LTP in stratum oriens of hippocampal CA1. Cereb Cortex 2012; 22: 1786-1798.
30. Davalos D, Lee JK, Smith WB, et al., Stable in vivo imaging of densely populated glia, axons and blood vessels in the mouse spinal cord using two-photon microscopy. J Neurosci Methods 2008; 169: 1-7.
31. Romanelli E, Sorbara CD, Nikic IN, et al., Cellular, subcellular and functional in vivo labeling of the spinal cord using vital dyes. Nat Protoc 2013; 8: 481-490.
32. Sorbara CD, Wagner NE, Ladwig A, et al., Pervasive axonal transport deficits in multiple sclerosis models. Neuron 2014; 84: 1183-1190.
33. Steinbach K, Merkler D,. Neuropathological techniques to investigate CNS pathology in experimental autoimmune encephalomyelitis (EAE). Methods Mol Biol 2016; 1304: 189-209.
34. Hale JE,. Irreversible, oriented immobilization of antibodies to cobalt-iminodiacetate resin for use as immunoaffinity media. Anal Biochem 1995; 231: 46-49.
35. Schindelin J, Arganda-Carreras I, Frise E, et al., Fiji: an open-source platform for biological-image analysis. Nat Methods 2012; 9: 676-682.
36. Zhang H, Bennett JL, Verkman AS,. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 2011; 70: 943-954.
37. Li P, Murphy TH,. Two-photon imaging during prolonged middle cerebral artery occlusion in mice reveals recovery of dendritic structure after reperfusion. J Neurosci 2008; 28: 11970-11979.
38. Eikermann-Haerter K, Arbel-Ornath M, Yalcin N, et al., Abnormal synaptic Ca2 + homeostasis and morphology in cortical neurons of familial hemiplegic migraine type 1 mutant mice. Ann Neurol 2015; 78: 193-210.
39. Marignier R, Nicolle A, Watrin C, et al., Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 2010; 133: 2578-2591.
40. Schreiner B, Romanelli E, Liberski P, et al., Astrocyte depletion impairs redox homeostasis and triggers neuronal loss in the adult CNS. Cell Rep 2015; 12: 1377-1384.
41. Delaney CL, Brenner M, Messing A,. Conditional ablation of cerebellar astrocytes in postnatal transgenic mice. J Neurosci 1996; 16: 6908-6918.
42. Bush TG, Puvanachandra N, Horner CH, et al., Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 1999; 23: 297-308.
43. Fern RF, Matute C, Stys PK,. White matter injury: ischemic and nonischemic. Glia 2014; 62: 1780-1789.
44. Cambron M, D'Haeseleer M, Laureys G, et al., White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis. J Cereb Blood Flow Metab 2012; 32: 413-424.
45. Nave KA,. Myelination and support of axonal integrity by glia. Nature 2010; 468: 244-252.
46. Nave KA, Trapp BD,. Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 2008; 31: 535-561.
47. Anderson CM, Swanson RA,. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 2000; 32: 1-14.
48. Pitt D, Werner P, Raine CS,. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000; 6: 67-70.
49. Newcombe J, Uddin A, Dove R, et al., Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 2008; 18: 52-61.
50. Smith T, Groom A, Zhu B, Turski L,. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000; 6: 62-66.
51. Stys PK,. General mechanisms of axonal damage and its prevention. J Neurol Sci 2005; 233: 3-13.
52. Hires SA, Zhu Y, Tsien RY,. Optical measurement of synaptic glutamate spillover and reuptake by linker optimized glutamate-sensitive fluorescent reporters. Proc Natl Acad Sci U S A 2008; 105: 4411-4416.
53. Siffrin V, Radbruch H, Glumm R, et al., In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 2010; 33: 424-436.
54. Hertz L, Peng L, Dienel GA,. Energy metabolism in astrocytes: high rate of oxidative metabolism and spatiotemporal dependence on glycolysis/glycogenolysis. J Cereb Blood Flow Metab 2007; 27: 219-249.
55. Bélanger M, Allaman I, Magistretti PJ,. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 2011; 14: 724-738.
56. Magistretti PJ,. Neuron-glia metabolic coupling and plasticity. J Exp Biol 2006; 209 (pt 12): 2304-2311.
57. Desagher S, Glowinski J, Premont J,. Astrocytes protect neurons from hydrogen peroxide toxicity. J Neurosci 1996; 16: 2553-2562.
58. Swanson RA, Ying W, Kauppinen TM,. Astrocyte influences on ischemic neuronal death. Curr Mol Med 2004; 4: 193-205.
59. Trendelenburg G, Dirnagl U,. Neuroprotective role of astrocytes in cerebral ischemia: focus on ischemic preconditioning. Glia 2005; 50: 307-320.
60. Papadopoulos MC, Verkman AS,. Aquaporin water channels in the nervous system. Nat Rev Neurosci 2013; 14: 265-277.
61. Ochs S, Pourmand R, Jersild RA, Friedman RN,. The origin and nature of beading: a reversible transformation of the shape of nerve fibers. Prog Neurobiol 1997; 52: 391-426.
62. Ratelade J, Verkman AS,. Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica. Mol Immunol 2014; 62: 104-113.
63. Kowarik MC, Dzieciatkowska M, Wemlinger S, et al., The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations. J Neuroinflammation 2015; 12: 19.